Cyxone provides an update on its research and development program
Cyxone (publ) is a biotech company with two promising clinical stage drug candidates, rabeximod and T20K, for autoimmune diseases. The company announces an updated development plan that aligns with the revised strategy revealed in August 2023, aiming to bring hope to patients suffering from these conditions.In April of this year, Kjell Stenberg, a seasoned leader in the biotech industry, was appointed as the company's new CEO. In collaboration with an external team of key opinion leaders and an internal team, Dr. Stenberg reviewed the latest findings for both the rabeximod and T20K projects.